Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

TU2218

orally administered

DRUG

Anti-PD-1 antibody

Intravenously administered

Trial Locations (3)

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors

lead

TiumBio Co., Ltd.

INDUSTRY